Tranexamic acid: Uses, Interactions, Mechanism of Action | DrugBank Online

Name: Tranexamic acid: Uses, Interactions, Mechanism of Action | DrugBank Online
Ingredients: Tranexamic acid (1.5 mg/30mg) + Arbutin (3 mg/30mg) + Glycerin (7.5 mg/30mg) + Hyaluronic acid (9 mg/30mg) + Nicotinamide (4.5 mg/30mg); Tranexamic acid (0.02 g/10mL) + Adenosine (0.004 g/10mL); Tranexamic acid (0.001 g/10mL) + Adenosine (0.004 g/10mL); Tranexamic acid (0.05 mg/50mL); Tranexamic acid (0.02 g/10mL) + Adenosine (0.004 g/10mL); Tranexamic acid (0.05 g/50mL); Tranexamic acid (0.001 g/10mL) + Adenosine (0.004 g/10mL)

go.drugbank.com

Your recipes

Tranexamic acid: Uses, Interactions, Mechanism of Action | DrugBank Online

Ingredients

Remove All · Remove Spices · Remove Staples

Tranexamic acid (1.5 mg/30mg) + Arbutin (3 mg/30mg) + Glycerin (7.5 mg/30mg) + Hyaluronic acid (9 mg/30mg) + Nicotinamide (4.5 mg/30mg)Tranexamic acid (0.02 g/10 milliliters) + Adenosine (0.004 g/10 milliliters)Tranexamic acid (0.001 g/10 milliliters) + Adenosine (0.004 g/10 milliliters)Tranexamic acid (0.05 mg/50 milliliters)Tranexamic acid (0.02 g/10 milliliters) + Adenosine (0.004 g/10 milliliters)Tranexamic acid (0.05 g/50 milliliters)Tranexamic acid (0.001 g/10 milliliters) + Adenosine (0.004 g/10 milliliters)

Export 5 ingredients for grocery delivery

Instructions

Helping creators monetize

Show ad-free recipes at the top of any site

Step 2

Furtmuller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H: Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther. 2002 Apr;301(1):168-73. doi: 10.1124/jpet.301.1.168. [Article] Ng W, Jerath A, Wasowicz M: Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther. 2015;47(4):339-50. doi: 10.5603/AIT.a2015.0011. Epub 2015 Mar 23. [Article] Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Watters D: C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005 Mar;139(3):379-94. doi: 10.1111/j.1365-2249.2005.02726.x. [Article] FDA Approved Drug Products: Cyklokapron (tranexamic acid) for intravenous injection [Link] FDA Approved Drug Products: Lysteda (tranexamic acid) tablets for oral use [Link] Health Canada Product Monograph: Cyklokapron (tranexamic acid) tablets for oral use [Link] CaymanChem: Tranexamic acid MSDS [Link]

Step 3

Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. [Article] Marti DN, Schaller J, Llinas M: Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains. Biochemistry. 1999 Nov 30;38(48):15741-55. [Article] Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth. 1999 Oct;83(4):596-601. [Article] Bangert K, Thorsen S: Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis. Thromb Haemost. 2000 Aug;84(2):299-306. [Article] Hanson AJ, Quinn MT: Effect of fibrin sealant composition on human neutrophil chemotaxis. J Biomed Mater Res. 2002 Sep 5;61(3):474-81. [Article] FDA Approved Drug Products: Lysteda (tranexamic acid) tablets for oral use [Link]